Carolyn Harris

It is a pleasure to serve under your chairmanship, Ms Jardine. I congratulate my hon. Friends the Members for Isle of Wight West (Mr Quigley) and for South Norfolk (Ben Goldsborough) on securing this vital debate on the histological testing of excised moles. I am chair of the all-party parliamentary group for beauty and wellbeing, and this issue aligns closely with our current inquiry into ultraviolet safety. It sits right at the heart of the concerns that led to the launch of the inquiry earlier this year. Unprotected UV exposure poses huge risks and is creating a greater volume of potentially malignant lesions. We know that it is the main driver of the formation of new moles and the malignant transformation of existing ones. As the number of cases escalates, so does the need for accurate and timely histological testing. The success of the entire melanoma pathway hinges on that final, non-negotiable diagnostic step. We must ensure that the NHS’s resources, training and standardisation for histological analysis are robust enough to manage the growing volume. Figures from Cancer Research UK paint a worrying picture: nearly 18,000 new cases of melanoma are diagnosed each year in the UK, and that is projected to rise to nearly 27,000 by 2040. The pressure on pathology services to diagnose excised lesions correctly and rapidly is immense, and it is only going to rise. What is perhaps more tragic is that 86% of these cancers are preventable. If people were better able to protect themselves against UV radiation, we could slash the number of cases and ease the burden on our health services. Our APPG inquiry into UV safety launched in May, and aims to take evidence from clinicians, academics, industry experts, media influencers and those with lived experience. Although we will not report until spring next year, we are already seeing patterns in the evidence we have received in oral sessions and through written submissions: calls for public awareness campaigns so that people are better educated on how to check their moles and seek medical intervention when needed; questions around the labelling of the sun protection factor and affordability of sun cream; and a widespread concern over the regulation and marketing of products that have known melanoma risk factors. I am sure the Minister will listen today and that she is acutely aware of the critical importance of this issue. We must resource diagnostic services appropriately to meet the rising demand, and at the same time give adequate attention to changes that will help to prevent the predicted rise in cases. By addressing in tandem prevention and detection—from SPF affordability, which will encourage sun cream use, to rapid histology, which will produce timely diagnoses—we will deliver the most significant savings of all. We will save families money, we will save patients long and anxious waits for test results, and we will save the NHS money by reducing costs and easing its burden. Most importantly, we will save lives.